HCA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
HCA Healthcare Inc is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has strong financial performance and positive analyst sentiment, the stock appears overvalued based on high valuation concerns and insider selling trends. Additionally, technical indicators suggest the stock is overbought, and short-term stock trend analysis indicates potential downside. Given the investor's preference for long-term stability, it would be prudent to hold off on investing in HCA at this time.
The stock is showing bullish momentum with MACD positively expanding, RSI at 76.799 indicating overbought conditions, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). However, the stock is nearing resistance levels (R1: 540.791, R2: 557.931), which could limit further upside in the short term.
Strong Q4 2025 financial performance with revenue up 6.72% YoY, net income up 30.60% YoY, and EPS up 44.58% YoY.
Positive analyst sentiment with multiple price target increases and strong 2026 guidance.
Bullish technical indicators.
Insider selling has increased significantly by 1438.91% in the last month.
The stock appears overvalued, with analysts noting it is at the high end of long-term valuation ranges.
Short-term stock trend analysis predicts potential downside (-1.3% next day, -2.43% next week, -11.55% next month).
HCA Healthcare reported strong Q4 2025 results with revenue of $19.51B (+6.72% YoY), net income of $1.878B (+30.60% YoY), EPS of $8.14 (+44.58% YoY), and gross margin of 80.07% (+0.04% YoY).
Analysts have raised price targets significantly, with the highest target at $598 (UBS) and the lowest at $481 (Wells Fargo). Most analysts maintain positive ratings, citing strong financial performance and 2026 guidance. However, some express concerns over high valuations and moderating growth rates.
